• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Ahmedabad, June 16

Cadila Healthcare Ltd (Zydus Cadila) on Monday announced the first day launch of Venlafaxine Hydrochloride tablets upon receiving the final approval from the US Food and Drug Administration (USFDA). The company is marketing the product in the strengths of 25, 37.5, 50,75 and 100 mg in the US market.

The sales of Venlafaxine hydrochloride, an anti-depressant, was estimated at $194 million in 2007, it said here in a statement.

This marks the 39th Abbreviated New Drug Application (ANDA) approval for the Group since the commencement of filing process in FY 2003-04. So far, the group has filed 78 ANDAs and 59 Drug Master Files.

More Stories on : Regulatory Bodies & Rulings | New Products & Services | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Piramal Life developing drug to tackle Glivec resistance

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line